Investor attention around CureVac (NasdaqGM:CVAC) has picked up after management outlined incremental progress in its second generation mRNA vaccine programs with GSK, along with a more focused ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market capitalization of $818.75 million, stands at a critical juncture in its ...

With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year and switching focus to a second mRNA asset with GlaxoSmithKline. A ...

Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with ...

A volunteer receives a dose of CureVac vaccine or a placebo, in Brussels (Reuters) - German biotechnology company CureVac NV said on Thursday clinical trials for its second-generation COVID-19 vaccine ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...

MUNICH (Reuters) - A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims ...

In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This ...

A German court has dealt the first blow against CureVac amid the company's heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech. The German Federal Patent Court ruled that ...